Radiotherapy could increase the efficacy of immunotherapy in non-small cell lung cancer

Background: In non-small cell lung cancer (NSCLC), immunotherapy is a treatment option in patients without targetable mutations second and later lines. Nevertheless, there no validated test that can predict response.
 Material Methods: Our study aimed to investigate the effect of radiotherapy (RT) on survival with NSCLC receiving after first-line chemotherapy. Twenty-five diagnosed received at least one previous chemotherapy line were included our study.
 Results: The median age was 61.7 (26.6-81.2) years. 19 (76%) male. 11 (44%) had second-line 14 (66%) ≥3 Patients 5 cycles (1-27) immunotherapy. RT interval 6.4 months (1.0-11.8). Partial response observed 12 patients, stable disease 8 progression 1 patient, hyperprogression 4 patients. Median progression-free (PFS) 4.4 (95% CI; 3.2-5.6), overall (OS) 16.4 5.6-27.3). (56%) RT. administered before immunotherapy, two bones during who statistically longer PFS (4.9 vs 3.9 months, p=0.012) OS (18.7 7.3 p=0.023) comparing those 
 Conclusions: findings showed significantly improved pointing may have an influential role response.